Pharmacogenetic variation and metformin response

Current Drug Metabolism

Volumn 14, Issue 10, 2013, Pages 1070-1082

  Chen, Suning ^a   Zhou, Jie ^a   Xi, Miaomiao ^a   Jia, Yanyan ^a   Wong, Yan ^a   Zhao, Jinyi ^a   Ding, Likun ^a   Zhang, Jian ^b   Wen, Aidong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

AMPK; MATE; Metformin; OCT; Pharmacogenetic; SNP; T2D

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; ATM PROTEIN; CATIONIC NEUROTRANSMITTER; CHOLINE; COCAINE; CREATININE; DOPAMINE; HEMOGLOBIN A1C; HISTAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; METHAMPHETAMINE; MULTIDRUG AND TOXIN EXTRUSION TRANSPORTER PROTEIN; NEUROTRANSMITTER; NORADRENALIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PLASMA MEMBRANE MONOAMINE TRANSPORTER PROTEIN; PROTEIN; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE 11; SEROTONIN; UNCLASSIFIED DRUG;

ADIPOCYTE; AFRICAN AMERICAN; ALLELE; ANTIDIABETIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASIAN; ATAXIA TELANGIECTASIA; BASOLATERAL MEMBRANE; BODY COMPOSITION; BODY MASS; BRUSH BORDER; CAUCASIAN; CELL CYCLE ARREST; CELL ENERGY; CHOROID PLEXUS; DNA DAMAGE CHECKPOINT; DNA REPAIR; DOSE RESPONSE; DOUBLE STRANDED DNA BREAK; DRUG BIOAVAILABILITY; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIUM CELL; EXON; FAT MASS; FATTY ACID OXIDATION; FATTY ACID SYNTHESIS; FUNCTIONAL ASSESSMENT; GENE DOSAGE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; GLYCEMIC CONTROL; GLYCOGEN SYNTHESIS; HETEROZYGOSITY; HETEROZYGOTE; HOMEOSTASIS; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; HYDROLYSIS; HYPERLACTATEMIA; IMPAIRED GLUCOSE TOLERANCE; IN VIVO STUDY; INCIDENCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTESTINE ABSORPTION; INTESTINE CELL; INTRON; JAPANESE; KIDNEY CLEARANCE; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE EXCRETION; LACTIC ACIDOSIS; LIPOGENESIS; LIPOLYSIS; LIVER CELL; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); METABOLIC STRESS; MUSCLE EXCITATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION; PANCREAS ISLET BETA CELL; PHARMACOGENETICS; PHENOTYPE; PLASMA CONCENTRATION-TIME CURVE; PREVALENCE; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SKELETAL MUSCLE; THERAPY EFFECT; TISSUE DISTRIBUTION; TREATMENT RESPONSE; URINARY EXCRETION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOLOGICAL AVAILABILITY; DIABETES MELLITUS, TYPE 2; GENETIC VARIATION; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; METABOLIC CLEARANCE RATE; METFORMIN; MUSCLES; ORGANIC CATION TRANSPORT PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN ISOFORMS; TISSUE DISTRIBUTION;

EID: 84891294952     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200214666131211153933     Document Type: Article

References (94)

1. Reitman, M.L.; Schadt, E.E. Pharmacogenetics of metformin response: A step in the path toward personalized medicine. J. Clin. Invest., 2007, 117 (5), 1226-9
2. Takane, H.; Shikata, E.; Otsubo, K.; Higuchi, S.; Ieiri, I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics, 2008, 9(4), 415-22.
3. Kirpichnikov, D.; McFarlane, S.I.; Sowers, J.R. Metformin: An update. Ann. Intern. Med., 2002, 137(1), 25-33.
4. Caton, P.W.; Nayuni, N.K.; Kieswich, J.; Khan, N.Q.; Yaqoob, M.M.; Corder, R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J. Endocrinol., 2010, 205(1), 97-106.
5. Shu, Y.; Brown, C.; Castro, R.A.; Shi, R J.; Lin, E.T.; Owen, R.P.; Sheardown, S.A.; Yue, L.; Burchard, E.G.; Brett, C.M.; Giacomini, K. M. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin. Pharmcol. Therapeut., 2008, 83(2), 273-80.
6. Graham, G.G.; Punt, J.; Arora, M.; Day, R.O.; Doogue, M.P.; Duong, J.K.; Furlong, T.J.; Greenfield, J.R.; Greenup, L.C.; Kirkpatrick, C.M.; Ray, J.E.; Timmins, P.; Williams, K.M. Clinical pharmacokinetics of metformin. Clin. Pharmacokinet., 2011, 50(2), 81-98.
7. Zamek-Gliszczynski, M. J.; Bao, J. Q.; Day, J. S.; Higgins, J. W. Metformin sinusoidal efflux from the liver is consistent with negligible biliary excretion and absence of enterohepatic cycling. Drug Metab. Dispos., 2013, 41(11), 1967-71.
8. Kim, R. B. Transporters and drug discovery: why, when, and how. Mol. Pharm., 2006, 3(1), 26-32
9. Wang, D. S.; Jonker, J. W.; Kato, Y.; Kusuhara, H.; Schinkel, A. H.; Sugiyama, Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther., 2002, 302(2), 510-5
10. Dresser, M. J.; Xiao, G.; Leabman, M. K.; Gray, A. T.; Giacomini, K. M. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm. Res., 2002, 19 (8), 1244-7
11. Kaewmokul, S.; Chatsudthipong, V.; Evans, K.K.; Dantzler, W.H.; Wright, S.H. Functional mapping of rbOCT1 and rbOCT2 activity in the S2 segment of rabbit proximal tubule. Am. J. Physiol. Renal Physiol., 2003, 285(6), F1149-59.
12. Brown, J.B.; Conner, C.; Nichols, G.A. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care, 2010, 33(3), 501-6.
13. Abou-Zeid, L.A.; El-Mowafy, A.M. Differential recognition of resveratrol isomers by the human estrogen receptor-alpha: molecular dynamics evidence for stereoselective ligand binding. Chirality, 2004, 16(3), 190-5.
14. Zhou, M.; Xia, L.; Wang, J. Metformin transport by a newly cloned proton-stimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab. Dispos., 2007, 35(10), 1956-62.
15. Nies, A.T.; Koepsell, H.; Winter, S.; Burk, O.; Klein, K.; Kerb, R.; Zanger, U.M.; Keppler, D.; Schwab, M.; Schaeffeler, E. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology, 2009, 50(4), 1227-40.
16. Kimura, N.; Masuda, S.; Tanihara, Y.; Ueo, H.; Okuda, M.; Katsura, T.; Inui, K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet., 2005, 20(5), 379-86.
17. Ahlin, G.; Chen, L.; Lazorova, L.; Chen, Y.; Ianculescu, A.G.; Davis, R.L.; Giacomini, K. M.; Artursson, P. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions. Pharmacogenom. J., 2011, 11(6), 400-11.
18. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res., 2007, 24(7), 1227-51.
19. Koepsell, H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol. Aspects Med., 2013, 34(2-3), 413-35.
20. Nies, A.T.; Koepsell, H.; Damme, K.; Schwab, M. Organic cation transporters (OCTs, MATEs), in vitro and in vivo evidence for the importance in drug therapy. Handb. Exp. Pharmacol., 2011, 201, 105-67.
21. Moreno-Navarrete, J.M.; Ortega, F.J.; Rodriguez-Hermosa, J.I.; Sabater, M.; Pardo, G.; Ricart, W.; Fernandez-Real, J. M. OCT1 Expression in adipocytes could contribute to increased metformin action in obese subjects. Diabetes, 2011, 60(1), 168-76
22. Shu, Y.; Sheardown, S.A.; Brown, C.; Owen, R.P.; Zhang, S.; Castro, R.A.; Ianculescu, A.G.; Yue, L.; Lo, J.C.; Burchard, E.G.; Brett, C.M.; Giacomini, K.M. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest., 2007, 117(5), 1422-31.
23. Umamaheswaran, G.; Praveen, R. G.; Arunkumar, A. S.; Das, A. K.; Shewade, D. G.; Adithan, C. Genetic analysis of OCT1 gene polymorphisms in an Indian population. Indian J. Hum. Genet., 2011, 17 (3), 164-8.
24. Chen, L.; Takizawa, M.; Chen, E.; Schlessinger, A.; Segenthelar, J.; Choi, J. H.; Sali, A.; Kubo, M.; Nakamura, S.; Iwamoto, Y.; Iwasaki, N.; Giacomini, K. M. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J. Pharmacol. Exp. Ther., 2010, 335(1), 42-50.
25. Gambineri, A.; Tomassoni, F.; Gasparini, D.I.; Di Rocco, A.; Mantovani, V.; Pagotto, U.; Altieri, P.; Sanna, S.; Fulghesu, A.M.; Pasquali, R. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2010, 95(10), E204-8.
26. Becker, M.L.; Visser, L.E.; van Schaik, R.H.; Hofman, A.; Uitterlinden, A.G.; Stricker, B.H. Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. Pharmacogenomics J., 2009, 9(4), 242-7.
27. Tarasova, L.; Kalnina, I.; Geldnere, K.; Bumbure, A.; Ritenberga, R.; Nikitina-Zake, L.; Fridmanis, D.; Vaivade, I.; Pirags, V.; Klovins, J. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients. Pharmacogenet. Genomics, 2012, 22 (9), 659-66.
28. Shikata, E.; Yamamoto, R.; Takane, H.; Shigemasa, C.; Ikeda, T.; Otsubo, K.; Ieiri, I. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet., 2007, 52 (2), 117-22
29. Pacanowski, M. A.; Hopley, C. W.; Aquilante, C. L. Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms. Expert Opin. Drug Metab. Toxicol., 2008, 4 (5), 529-44.
30. Choi, M. K.; Song, I. S. Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake. Biopharm. Drug Dispos., 2012, 33 (3), 170-8.
31. Leabman, M. K.; Huang, C. C.; DeYoung, J.; Carlson, E. J.; Taylor, T. R.; de la Cruz, M.; Johns, S. J.; Stryke, D.; Kawamoto, M.; Urban, T. J.; Kroetz, D. L.; Ferrin, T. E.; Clark, A. G.; Risch, N.; Herskowitz, I.; Giacomini, K. M. Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl. Acad. Sci. U. S. A., 2003, 100 (10), 5896-901
32. Sakata, T.; Anzai, N.; Shin, H. J.; Noshiro, R.; Hirata, T.; Yokoyama, H.; Kanai, Y.; Endou, H. Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem. Biophys. Res. Commun., 2004, 313 (3), 789-93
33. Shu, Y.; Leabman, M. K.; Feng, B.; Mangravite, L. M.; Huang, C. C.; Stryke, D.; Kawamoto, M.; Johns, S. J.; DeYoung, J.; Carlson, E.; Ferrin, T. E.; Herskowitz, I.; Giacomini, K. M. Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl. Acad. Sci. U.S.A., 2003, 100 (10), 5902-7
34. Kerb, R.; Brinkmann, U.; Chatskaia, N.; Gorbunov, D.; Gorboulev, V.; Mornhinweg, E.; Keil, A.; Eichelbaum, M.; Koepsell, H. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics, 2002, 12 (8), 591-5.
35. Chen, Y.; Li, S.; Brown, C.; Cheatham, S.; Castro, R. A.; Leabman, M. K.; Urban, T. J.; Chen, L.; Yee, S. W.; Choi, J. H.; Huang, Y.; Brett, C. M.; Burchard, E. G.; Giacomini, K. M. Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin. Pharmacogenet. Genomics, 2009, 19 (7), 497-504.
36. Koepsell, H.; Endou, H. The SLC22 drug transporter family. Pflugers Arch., 2004, 447 (5), 666-76;
37. Motohashi, H.; Uwai, Y.; Hiramoto, K.; Okuda, M.; Inui, K. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol., 2004, 503 (1-3), 25-30.
38. Jonker, J. W.; Schinkel, A. H. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther., 2004, 308 (1), 2-9
39. Koepsell, H. Polyspecific organic cation transporters: their functions and interactions with drugs. Trends Pharmacol. Sci., 2004, 25 (7), 375-81.
40. Christensen, M. M.; Pedersen, R. S.; Stage, T. B.; Brasch- Andersen, C.; Nielsen, F.; Damkier, P.; Beck-Nielsen, H.; Brosen, K. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet. Genomics, 2013, 23 (10), 526-34.
41. Konig, J.; Zolk, O.; Singer, K.; Hoffmann, C.; Fromm, M. F. Double- transfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br. J. Pharmacol., 2011, 163 (3), 546-55.
42. Song, I. S.; Lee do, Y.; Shin, M. H.; Kim, H.; Ahn, Y. G.; Park, I.; Kim, K. H.; Kind, T.; Shin, J. G.; Fiehn, O.; Liu, K. H. Pharmacogenetics Meets Metabolomics: Discovery of Tryptophan as a New Endogenous OCT2 Substrate Related to Metformin Disposition. PLoS One, 2012, 7 (5), e36637.
43. Wang, Z. J.; Yin, O. Q.; Tomlinson, B.; Chow, M. S. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenet. Genomics, 2008, 18 (7), 637-45.
44. Song, I. S.; Shin, H. J.; Shim, E. J.; Jung, I. S.; Kim, W. Y.; Shon, J. H.; Shin, J. G. Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther., 2008, 84 (5), 559-62.
45. Song, I.S.; Shin, H.J.; Shin, J.G. Genetic variants of organic cation transporter 2 (OCT2) significantly reduce metformin uptake in oocytes. Xenobiotica, 2008, 38(9), 1252-62.
46. Chen, L.; Pawlikowski, B.; Schlessinger, A.; More, S.S.; Stryke, D.; Johns, S.J.; Portman, M.A.; Chen, E.; Ferrin, T.E.; Sali, A.; Giacomini, K.M. Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin. Pharmacogenet. Genomics, 2010, 20(11), 687-99.
47. Amphoux, A.; Vialou, V.; Drescher, E.; Bruss, M.; Mannoury La Cour, C.; Rochat, C.; Millan, M.J.; Giros, B.; Bonisch, H.; Gautron, S. Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology, 2006, 50(8), 941-52
48. Yokoo, S.; Masuda, S.; Yonezawa, A.; Terada, T.; Katsura, T.; Inui, K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab. Dispos., 2008, 36(11), 2299-306.
49. Somogyi, A.; Stockley, C.; Keal, J.; Rolan, P.; Bochner, F. Reduction of metformin renal tubular secretion by cimetidine in man. Br. J. Clin. Pharmacol., 1987, 23 (5), 545-51.
50. Dean, M.; Annilo, T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu. Rev. Genomics Hum. Genet., 2005, 6, 123-42.
51. Otsuka, M.; Matsumoto, T.; Morimoto, R.; Arioka, S.; Omote, H.; Moriyama, Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. U.S.A., 2005, 102 (50), 17923-8
52. Masuda, S.; Terada, T.; Yonezawa, A.; Tanihara, Y.; Kishimoto, K.; Katsura, T.; Ogawa, O.; Inui, K. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol., 2006, 17(8), 2127-35.
53. Gong, L.; Goswami, S.; Giacomini, K.M.; Altman, R.B.; Klein, T.E. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet. Genomics, 2012, 22(11), 820-7.
54. Toyama, K.; Yonezawa, A.; Tsuda, M.; Masuda, S.; Yano, I.; Terada, T.; Osawa, R.; Katsura, T.; Hosokawa, M.; Fujimoto, S.; Inagaki, N.; Inui, K. Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet. Genomics, 2010, 20(2), 135-8.
55. Tsuda, M.; Terada, T.; Mizuno, T.; Katsura, T.; Shimakura, J.; Inui, K. Targeted disruption of the multidrug and toxin extrusion 1 (mate1) gene in mice reduces renal secretion of metformin. Mol. Pharmacol., 2009, 75(6), 1280-6.
56. Toyama, K.; Yonezawa, A.; Masuda, S.; Osawa, R.; Hosokawa, M.; Fujimoto, S.; Inagaki, N.; Inui, K.; Katsura, T. Loss of multidrug and toxin extrusion 1 (MATE1) is associated with metformin- induced lactic acidosis. Br. J. Pharmacol., 2012, 166(3), 1183-91.
57. Becker, M.L.; Visser, L.E.; van Schaik, R.H.; Hofman, A.; Uitterlinden, A. G.; Stricker, B. H. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucoselowering effect of metformin in patients with diabetes: A preliminary study. Diabetes, 2009, 58(3), 745-9.
58. Becker, M.L.; Visser, L.E.; van Schaik, R.H.; Hofman, A.; Uitterlinden, A. G.; Stricker, B. H. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet. Genomics, 2010, 20(1), 38-44.
59. Kajiwara, M.; Terada, T.; Ogasawara, K.; Iwano, J.; Katsura, T.; Fukatsu, A.; Doi, T.; Inui, K. Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J. Hum. Genet., 2009, 54 (1), 40-6.
60. Chen, Y.; Teranishi, K.; Li, S.; Yee, S.W.; Hesselson, S.; Stryke, D.; Johns, S.J.; Ferrin, T.E.; Kwok, P.; Giacomini, K. M. Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function. Pharmacogenomics J., 2009, 9(2), 127-36.
61. Choi, J.H.; Yee, S.W.; Ramirez, A.H.; Morrissey, K.M.; Jang, G.H.; Joski, P.J.; Mefford, J.A.; Hesselson, S.E.; Schlessinger, A.; Jenkins, G.; Castro, R.A.; Johns, S.J.; Stryke, D.; Sali, A.; Ferrin, T.E.; Witte, J.S.; Kwok, P.Y.; Roden, D.M.; Wilke, R.A.; McCarty, C.A.; Davis, R.L.; Giacomini, K.M. A common 5'-UTR variant in MATE2-K is associated with poor response to metformin. Clin. Pharmacol. Ther., 2011, 90(5), 674-84.
62. Damme, K.; Nies, A.T.; Schaeffeler, E.; Schwab, M. Mammalian MATE (SLC47A) transport proteins: Impact on efflux of endogenous substrates and xenobiotics. Drug Metab. Rev., 2011, 43(4), 499-523.
63. Winder, W.W.; Hardie, D.G. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am. J. Physiol., 1999, 277(1 Pt 1), E1-10.
64. Stapleton, D.; Mitchelhill, K.I.; Gao, G.; Widmer, J.; Michell, B.J.; Teh, T.; House, C.M.; Fernandez, C.S.; Cox, T.; Witters, L.A.; Kemp, B.E. Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem., 1996, 271(2), 611-4.
65. Thomson, D.M.; Porter, B.B.; Tall, J.H.; Kim, H.J.; Barrow, J.R.; Winder, W. W. Skeletal muscle and heart LKB1 deficiency causes decreased voluntary running and reduced muscle mitochondrial marker enzyme expression in mice. Am. J. Physiol. Endocrinol. Metab., 2007, 292(1), E196-202
66. Ojuka, E.O. Role of calcium and AMP kinase in the regulation of mitochondrial biogenesis and GLUT4 levels in muscle. Proc. Nutr. Soc., 2004, 63(2), 275-8;
67. Durante, P.E.; Mustard, K.J.; Park, S.H.; Winder, W.W.; Hardie, D.G. Effects of endurance training on activity and expression of AMP-activated protein kinase isoforms in rat muscles. Am. J. Physiol. Endocrinol. Metab., 2002, 283(1), E178-86
68. Bergeron, R.; Russell, R.R., 3rd; Young, L.H.; Ren, J.M.; Marcucci, M.; Lee, A.; Shulman, G.I. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am. J. Physiol., 1999, 276(5 Pt 1), E938-44
69. Winder, W. W., Energy-sensing and signaling by AMP-activated protein kinase in skeletal muscle. J. Appl. Physiol., 2001, 91(3), 1017-28.
70. Suter, M.; Riek, U.; Tuerk, R.; Schlattner, U.; Wallimann, T.; Neumann, D. Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J. Biol. Chem., 2006, 281(43), 32207-16.
71. Hardie, D.G., AMP-activated protein kinase as a drug target. Annu. Rev. Pharmacol. Toxicol., 2007, 47, 185-210.
72. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M.F.; Goodyear, L.J.; Moller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest., 2001, 108(8), 1167-74
73. Musi, N.; Hirshman, M.F.; Nygren, J.; Svanfeldt, M.; Bavenholm, P.; Rooyackers, O.; Zhou, G.; Williamson, J.M.; Ljunqvist, O.; Efendic, S.; Moller, D.E.; Thorell, A.; Goodyear, L.J. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 2002, 51(7), 2074-81.
74. Sun, M.W.; Lee, J.Y.; de Bakker, P.I.; Burtt, N.P.; Almgren, P.; Rastam, L.; Tuomi, T.; Gaudet, D.; Daly, M.J.; Hirschhorn, J.N.; Altshuler, D.; Groop, L.; Florez, J. C. Haplotype structures and large-scale association testing of the 5' AMP-activated protein kinase genes PRKAA2, PRKAB1, and PRKAB2 [corrected] with type 2 diabetes. Diabetes, 2006, 55(3), 849-55.
75. Jablonski, K.A.; McAteer, J.B.; de Bakker, P.I.; Franks, P.W.; Pollin, T.I.; Hanson, R.L.; Saxena, R.; Fowler, S.; Shuldiner, A.R.; Knowler, W.C.; Altshuler, D.; Florez, J.C. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes, 2010, 59(10), 2672-81.
76. Mahata, S.; Bharti, A.C.; Shukla, S.; Tyagi, A.; Husain, S.A.; Das, B.C. Berberine modulates AP-1 activity to suppress HPV transcription and downstream signaling to induce growth arrest and apoptosis in cervical cancer cells. Mol. Cancer, 2011, 10, 39.
77. Lopez-Bermejo, A.; Diaz, M.; Moran, E.; de Zegher, F.; Ibanez, L. A single nucleotide polymorphism in STK11 influences insulin sensitivity and metformin efficacy in hyperinsulinemic girls with androgen excess. Diabetes Care, 2010, 33(7), 1544-8.
78. Schroner, Z.; Dobrikova, M.; Klimcakova, L.; Javorsky, M.; Zidzik, J.; Kozarova, M.; Hudakova, T.; Tkacova, R.; Salagovic, J.; Tkac, I. Variation in KCNQ1 is associated with therapeutic response to sulphonylureas. Med. Sci. Monit., 2011, 17(7), CR392-6.
79. Franks, P.W.; Jablonski, K.A.; Delahanty, L.M.; McAteer, J.B.; Kahn, S.E.; Knowler, W.C.; Florez, J.C. Diabetes Prevention Program Research, G., Assessing gene-treatment interactions at the FTO and INSIG2 loci on obesity-related traits in the Diabetes Prevention Program. Diabetologia, 2008, 51(12), 2214-23.
80. Lee, J.H.; Paull, T.T., Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene, 2007, 26(56), 7741-8.
81. van Leeuwen, N.; Nijpels, G.; Becker, M.L.; Deshmukh, H.; Zhou, K.; Stricker, B.H.; Uitterlinden, A.G.; Hofman, A.; van 't Riet, E.; Palmer, C.N.; Guigas, B.; Slagboom, P.E.; Durrington, P.; Calle, R. A.; Neil, A.; Hitman, G.; Livingstone, S.J.; Colhoun, H.; Holman, R.R.; McCarthy, M.I.; Dekker, J.M.; Hart, L.M.; Pearson, E.R. A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: A replication and metaanalysis of five cohorts. Diabetologia, 2012, 55(7), 1971-7.
82. Zhou, K.; Bellenguez, C.; Spencer, C.C.; Bennett, A.J.; Coleman, R.L.; Tavendale, R.; Hawley, S.A.; Donnelly, L.A.; Schofield, C.; Groves, C.J.; Burch, L.; Carr, F.; Strange, A.; Freeman, C.; Blackwell, J.M.; Bramon, E.; Brown, M.A.; Casas, J.P.; Corvin, A.; Craddock, N.; Deloukas, P.; Dronov, S.; Duncanson, A.; Edkins, S.; Gray, E.; Hunt, S.; Jankowski, J.; Langford, C.; Markus, H.S.; Mathew, C.G.; Plomin, R.; Rautanen, A.; Sawcer, S.J.; Samani, N.J.; Trembath, R.; Viswanathan, A.C.; Wood, N.W.; Harries, L.W.; Hattersley, A.T.; Doney, A.S.; Colhoun, H.; Morris, A.D.; Sutherland, C.; Hardie, D.G.; Peltonen, L.; McCarthy, M.I.; Holman, R.R.; Palmer, C.N.; Donnelly, P.; Pearson, E. R. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat. Genet., 2011, 43(2), 117-120.
83. Zhou, K.; Donnelly, L.A.; Kimber, C.H.; Donnan, P.T.; Doney, A. S.; Leese, G.; Hattersley, A.T.; McCarthy, M.I.; Morris, A.D.; Palmer, C.N.; Pearson, E.R. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: A GoDARTS study. Diabetes, 2009, 58 (6), 1434-9.
84. Tzvetkov, M.V.; Vormfelde, S.V.; Balen, D.; Meineke, I.; Schmidt, T.; Sehrt, D.; Sabolic, I.; Koepsell, H.; Brockmoller, J. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Therapeut., 2009, 86(3), 299-306.
85. Duong, J.K.; Kumar, S.S.; Kirkpatrick, C.M.; Greenup, L.C.; Arora, M.; Lee, T.C.; Timmins, P.; Graham, G.G.; Furlong, T.J.; Greenfield, J.R.; Williams, K.M.; Day, R.O. Population Pharmacokinetics of Metformin in Healthy Subjects and Patients with Type 2 Diabetes Mellitus: Simulation of Doses According to Renal Function. Clin. Pharmacokinet., 2013, 52(5), 373-384.
86. Zolk, O.; Solbach, T.F.; Konig, J.; Fromm, M.F. Functional characterization of the human organic cation transporter 2 variant p.270Ala>Ser. Drug Metab. Dispos., 2009, 37 (6), 1312-8.
87. Li, Q.; Liu, F.; Zheng, T.S.; Tang, J.L.; Lu, H.J.; Jia, W.P. SLC22A2 gene 808 G/T variant is related to plasma lactate concentration in Chinese type 2 diabetics treated with metformin. Acta Pharmacol. Sin., 2010, 31(2), 184-90.
88. Meyer zu Schwabedissen, H.E.; Verstuyft, C.; Kroemer, H.K.; Becquemont, L.; Kim, R.B. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am. J. Physiol. Renal Physiol., 2010, 298(4), F997-F1005.
89. Florez, J. C.; Jablonski, K. A.; Sun, M. W.; Bayley, N.; Kahn, S. E.; Shamoon, H.; Hamman, R. F.; Knowler, W. C.; Nathan, D. M.; Altshuler, D. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J. Clin. Endocrinol. Metab., 2007, 92(4), 1502-9.
90. Hansen, L.; Ekstrom, C. T.; Tabanera, Y. P. R.; Anant, M.; Wassermann, K.; Reinhardt, R. R. The Pro12Ala variant of the PPARG gene is a risk factor for peroxisome proliferator-activated receptorgamma/ alpha agonist-induced edema in type 2 diabetic patients. J. Clin. Endocrinol. Metab., 2006, 91(9), 3446-50.
91. Javorsky, M.; Klimcakova, L.; Schroner, Z.; Zidzik, J.; Babjakova, E.; Fabianova, M.; Kozarova, M.; Tkacova, R.; Salagovic, J.; Tkac, I. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas. Eur. J. Intern. Med., 2012, 23(3), 245-9.
92. Pearson, E.R.; Donnelly, L.A.; Kimber, C.; Whitley, A.; Doney, A. S.; McCarthy, M.I.; Hattersley, A.T.; Morris, A.D.; Palmer, C.N. Variation in TCF7L2 influences therapeutic response to sulfonylureas: A GoDARTs study. Diabetes, 2007, 56(8), 2178-82.
93. Christensen, M.M.; Brasch-Andersen, C.; Green, H.; Nielsen, F.; Damkier, P.; Beck-Nielsen, H.; Brosen, K. The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenet. Genomics, 2011, 21(12), 837-50.
94. Pollin, T.I.; Jablonski, K.A.; McAteer, J.B.; Saxena, R.; Kathiresan, S.; Kahn, S.E.; Goldberg, R.B.; Altshuler, D.; Florez, J.C.; Diabetes Prevention Program Research, G. Triglyceride response to an intensive lifestyle intervention is enhanced in carriers of the GCKR Pro446Leu polymorphism. J. Clin. Endocrinol. Metab., 2011, 96(7), E1142-7.